What's new? Log in Free sign up

GH Research (GHRS)

Company Profile

Company profile

Ticker

GHRS

Exchange

Website

CEO

Dr. Velichka Valcheva M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Blue Water Biotech, Inc., Blue Water Vaccines Inc.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

GHRS stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Canaccord Genuity

Latest filings (excl ownership)

View all

Current report (foreign)

Prospectus supplement for primary offering

GH Research Announces Pricing of $150 Million Public Offering

Prospectus supplement for primary offering

GH Research Announces Proposed Public Offering

Current report (foreign)

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Current report (foreign)

Current report (foreign)

Latest ownership filings

View all

RA CAPITAL MANAGEMENT, L.P.

Lynx1 Capital Management LP

Lynx1 Capital Management LP

Venrock Healthcare Capital Partners II, L.P.

RA CAPITAL MANAGEMENT, L.P.

BIOTECHNOLOGY VALUE FUND L P

RTW INVESTMENTS, LP

RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL MANAGEMENT, L.P.

Financial summary

Financial statements Chart GHRS financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from GH Research earnings reports.

Institutional ownership, Q3 2024

GHRS institutional ownership history Ownership history

83.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	30	31	-3.2%
Opened positions	4	2	+100.0%
Closed positions	5	5	–
Increased positions	6	8	-25.0%
Reduced positions	8	7	+14.3%

13F shares	Current	Prev Q	Change
Total value	204.14 bn	354.54 bn	-42.4%
Total shares	43.31 mm	43.22 mm	+0.2%
Total puts	3.80 k	1.90 k	+100.0%
Total calls	2.80 k	63.10 k	-95.6%
Total put/call ratio	1.4	0.0	+4407.1%

Largest owners	Shares	Value	Change
BVF	10.40 mm	$69.58 bn	0.0%
Biotechnology Value Fund L P	9.28 mm	$0.00	0.0%
Ra Capital Management	6.69 mm	$44.73 bn	+1.3%
Lynx1 Capital Management	4.20 mm	$28.07 bn	+5.8%
Venrock Healthcare Capital Partners II	3.52 mm	$0.00	0.0%
RTW Investments	3.33 mm	$22.26 bn	0.0%
FMR	2.75 mm	$18.37 bn	-7.4%
Verition Fund Management	1.06 mm	$7.08 bn	-7.3%
Cormorant Asset Management	593.04 k	$3.97 bn	0.0%
5AM Venture Management	572.67 k	$3.83 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
Lynx1 Capital Management	4.20 mm	+229.17 k	+5.8%
FMR	2.75 mm	-220.93 k	-7.4%
Ra Capital Management	6.69 mm	+85.00 k	+1.3%
Verition Fund Management	1.06 mm	-82.85 k	-7.3%
BlackRock	64.89 k	+64.89 k	NEW
BLK BlackRock	0.00	-60.47 k	EXIT
Citadel Advisors	215.72 k	+58.23 k	+37.0%
Woodline Partners	37.24 k	+37.24 k	NEW
MS Morgan Stanley	258.62 k	-33.33 k	-11.4%
NTRS Northern Trust	32.19 k	+32.19 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

GH Research Commences Public Offering Of $150M Of Ordinary Shares

In addition, GH Research PLC intends to grant the underwriters an option to purchase up to an additional $22.5 million of ordinary shares at the public offering price, less underwriting discounts and commissions.

Crude Oil Moves Higher; Owens & Minor Shares Plummet

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday

Press releases

From Benzinga Pro

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.